Helping Cancer-Fighting T Cells Go Further: MEK Inhibition Reveals the Energy Cost of Exhaustion
Continuously producing cancer-killing proteins may impose an unsustainable metabolic cost on T cells. A preclinical study found that inhibiting MEK can prolong cell survival while weakening immediate attack capacity, revealing a balance that immunotherapy must strike.